POPULARITY
112 episodes with fda approval
68 episodes with fda approval
59 episodes with fda approval
26 episodes with fda approval
21 episodes with fda approval
12 episodes with fda approval
15 episodes with fda approval
9 episodes with fda approval
6 episodes with fda approval
5 episodes with fda approval
6 episodes with fda approval
4 episodes with fda approval
3 episodes with fda approval
3 episodes with fda approval
7 episodes with fda approval
4 episodes with fda approval
4 episodes with fda approval
4 episodes with fda approval
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show
Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial. We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life. Key topics covered in this episode: Overview of the SERENA-6 trial and its findings The role of ESR1 mutations in treatment resistance The efficacy and safety profile of camizestrant Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice Management of side effects, including bradycardia and QT prolongation Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers
Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV). The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea. Key topics covered in this episode included: Overview of the SURPASS-ET study and its significance Efficacy and tolerability of ropeginterferon alfa-2b in ET Side effect profiles of ropeginterferon alfa-2b vs anagrelide The importance of monitoring JAK2 allele burden and its clinical relevance Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics! #EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers
In his weekly clinical update, Daniel Griffin and Vincent Racaniello delve into dengue virus infections in Florida, recent human rabies infections in the US, proposed changes in biomedical funding including "converting" the Department of War into NIAID, the continuing controversy over the deaths of 2 children in Pennsylvania from measles, before Dr. Griffin deep dives into recent statistics RSV, influenza, SARS-CoV-2 infections, approval of new mRNA COVID-19 vaccines by the FDA, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Dengue in Florida: Florida Arbovirus Surveillance (Florida Health) Nationwide Increase in Reported Human Rabies Exposures: Rabies Post-exposure Prophylaxis Administration (CDC: Health Alert Network) NIH proposes major revamp of how it scores research grant proposals (Nature) Revealed: inside the US military's plan to tap huge sums from the NIH (Nature) Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2025 (CDC:MMWR) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Notes from the Field: Clinical Characteristics of Patients with Ebola Disease Caused by Bundibugyo Virus — Uganda, 2026 (CDC: MMWR) Notes from the Field: Characteristics and Monitoring of the 2026 Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo, August 2026 (CDC:MMWR) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Measles (Commonwealth of Pennsylvania) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Pennsylvania Department of Health Confirms Two Measles-Associated Deaths (Commonwealth of Pennsylvania) One of two measles-related deaths of unvaccinated people in Pennsylvania was an infant (CNN) Kennedy suggests measles deaths fabricated by PA governors (X) Measles Cases and Outbreaks (CDC: Rubeola) The CDC hasn't added 2 deaths to its measles database Why? (Washington Post) Trump's new CDC director ordered delay in counting 2 measles-related deaths (CNN) Commissioner Josh Parsons: Important information about measles (X) Laboratory Testing for Measles (CDC: Measles (Rubeola) Measles Clinical Diagnosis Fact Sheet (CDC: Measles (Rubeola) Measles Serology Testing (CDC: Measles (Rubeola) The Measles-Stricken Mother Who Lost Her Newborn Son (The Atlantic) What We Know About Pennsylvania's Two 'Measles-Associated' Deaths (FactCheck.org) What Obstetric Health Care Providers Need to Know About Measles and Pregnancy (Obstetrics & Gynecology) Measles and Pregnancy: Immunity and Immunization—What Can Be Learned from Observing Complications during an Epidemic Year(Journal of Pregnancy) Measles in pregnancy (cmaj: Canadian Medical Association Journal) Physician's Handbook on Medical Certification of Death (CDC: National Center for Health Statistics) CIDRAP Op-Ed: 'Died with, not from' was a real COVID problem. It's the wrong framework for measles. (CIDRAP) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization (Pediatrics) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Moderna) Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season (novavax) Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Pfizer) FDA approves new COVID vaccines (CIDRAP) COVID-19 vaccination and risk of post-COVID-19 cardiovascular disease: a population-based cohort and target trial emulation study (EHJ-QCCO) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1356 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
In his weekly clinical update, Daniel Griffin and Vincent Racaniello remember Dolly Parton and her patronage of science, especially development of the COVID-19 vaccines, if the shingles vaccine protect against cardiovascular events as well as dementia, the continued national cyclosporiasis and screwworm outbreaks, size of the Ebola outbreak in the Congo, the death of 2 children in Pennsylvania from measles and the economic cost of the measles outbreak, before Dr. Griffin deep dives into how to determine the case fatality rate of measles as well as measles outbreaks, recent statistics RSV, influenza, SARS-CoV-2 infections, approval of new mRNA COVID-19 vaccines by the FDA, access and how pay for Paxlovid, where to go for answers about long COVID-19, clinical guidelines for treating long COVID, B-cells-autoimmunity- long COVID, enrolling in a long COVID trial and the use of the COVID antiviral drug to "sop up" chronic virus shedding and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Dolly Parton adapts her song Jolene as she receives Covid-19 vaccine she helped fund (YouTube) Dolly Parton's major contributions to vaccines and public health (the bmj) Recombinant shingles vaccination and the risk of cardiovascular events (Nature Medicine) Surveillance of Cyclosporiasis (CDC: Cyclosporiasis) Infectious DiseaseOutbreaks (Michigan: Health & Human Services) Cyclosporiasis Cases in North Carolina (North Carolina: Division of Public Health) Cyclospora Infection (Cyclosporiasis) (NYC Health) Missouri Communicable Disease Report (2026) (Missouri Health) TWiP 285: Why is cyclospora hard to contain: Parasitologists explain the 2026 US outbreak (microbeTV:TWiP) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle(FDA) History of Ebola Outbreaks (CDC: Ebola) Democratic Republic of the Congo (OCHA) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo(WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles (Commonwealth of Pennsylvania) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Two more kids die. And one more theater show. (Your Local Epidemiologist) RFK Jr. says Shapiro's office may have fabricated measles deaths (Politico) ROBERT F. KENNEDY JR. SPEAKS OUT ABOUT VACCINES (Lancaster Patriot) Coroner says baby with measles in Pennsylvania died of a ruptured spleen (NBC News) Chapter 13: Measles (CDC: Epidemiology and Prevention of Vaccine-preventable Diseases) Challenges in measuring measles case fatality ratios in settings without vital registration (Emerging Themes in Epidemiology) High attack rates and case fatality during a measles outbreak in groups with religious exemption to vaccination (The Pediatric Infectious Disease Journal) Oz: MMR vaccine 'is not a lethal vaccine' (The Hill) RFK Jr: Secretary of Measlesland (Substack: Beyond the Noise) 'Brady Bunch' episode fuels campaigns against vaccines and Marcia's miffed (MPRNews) Use of Nowcasting to Estimate Real-Time Transmission Trends During a Measles Outbreak — South Carolina, October 2025–March 2026 (CDC:MMWR) Fighting measles is expensive. See what it cost to contain 10 cases (Washington Post) 'An ounce of prevention is worth a pound of cure' (Netherlands Heart Journal) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Heterogeneity of Airborne Virus Transmission in the Built Environment: A Narrative Review (Pathogens and Immunity) Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Moderna) Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season (novavax) Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Pfizer) FDA approves new COVID vaccines (CIDRAP) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID A distinct effector B cell population drives autoantibody production in SARS-CoV-2 infection (Immunity) Rapid recruitment for a remote long COVID clinical trial (LANCET:Infectious Diseases) Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVID (medrxiv) Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial (LANCET: Infectious Diseases) Reaching out to US house representative Letters read on TWiV 1354 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications. Key topics discussed included: The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies Insights into dosing, side effects, and the drug's impact on patient quality of life Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes! #Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The current landscape in the pharmaceutical and biotech industries is a tapestry of dynamic mergers, clinical trial advancements, regulatory approvals, and strategic partnerships. A major highlight is Eli Lilly's acquisition of Merida Biosciences for up to $2.9 billion. This move exemplifies the industry's strategic focus on expanding portfolios specifically in autoimmune and allergic diseases. Merida's precision degradation platform is set to significantly enhance Eli Lilly's capabilities, offering potential novel therapies that could address unmet needs in these therapeutic areas. Regulatory developments continue to shape the trajectory of this industry. The FDA's approval of Protagonist Therapeutics' Mimrylo (rusfertide) for polycythemia vera marks a significant advancement in peptide therapy. This hepcidin mimetic offers a novel approach to regulate hematocrit levels, addressing a critical need in managing this blood disorder. Additionally, the FDA has expanded PharmaEssentia's Besremi (ropeginterferon alfa-2b) label to include essential thrombocythemia regardless of genotype, broadening its applicability in myeloproliferative neoplasms. The approval of Stelara (ustekinumab) for pediatric patients with ulcerative colitis underscores an ongoing commitment to developing therapies for autoimmune conditions by utilizing monoclonal antibodies targeting IL-12/IL-23 pathways. Clinical trial outcomes continue to underscore the potential transformative impact of advanced therapeutics on patient care. Jazz Pharmaceuticals' Ziihera (zanidatamab) achieved a second overall survival win in a Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, reinforcing the promise of bispecific antibodies in oncology. In cardiovascular health, AstraZeneca's AZD5462, an oral relaxin agonist, demonstrated promise in a Phase 2 trial for chronic heart failure, showcasing the potential of small molecule therapeutics in this field. Additionally, Arrowhead Pharmaceuticals' Redemplo (plozasiran) Phase 3 data supports label expansion efforts for severe hypertriglyceridemia through RNA interference technology targeting the ApoC3 gene. The industry also continues to witness promising partnerships aimed at leveraging cutting-edge technologies. Mission Therapeutics and Neurolight are collaborating to deploy brain function biomarkers in Parkinson's disease trials, linking diagnostics and digital health innovations. Meanwhile, Create Medicines and Westgene Biopharma are advancing in vivo CAR therapies using targeted lipid nanoparticle delivery technology—a significant step forward in cell and gene therapy. Despite these positive developments, challenges persist. BioNTech's halt of its Phase 2 trial of an mRNA vaccine for colorectal cancer due to futility highlights the inherent uncertainties in drug development, particularly within innovative domains like personalized neoantigen therapies. Financial strategies remain pivotal as companies like Electra Therapeutics file IPOs to advance their immunology and cancer pipeline assets, indicating robust investor interest in these high-potential areas. Quoin Pharmaceuticals' planned $50 million private placement signifies strategic capital infusion towards rare and orphan disease development. In terms of sustainability, efforts within healthcare are gaining momentum as organizations like UCI Health and Kaiser Permanente explore electrification as part of their environmental agendas. These initiatives reflect a broader trend towards reducing healthcare's carbon footprint, highlighting the sector's role in addressing climate change. Finally, regulatory landscapes continue to evolve with legal challenges as Florida's Attorney General sues Express Scripts and Prime Therapeutics over alleged price-fixing. This lawsuit underscores ongoing scrutiny over pharmacy benefit managers' practices, potentially prompting regulatory reforms to ensure fair pricing mechanisms within the pharmaceutical supply chain. Overall, these developments illustrate a dynamic landscape where scientific innovation and regulatory maneuvers intersect to shape future pharmaceutical and biotech trajectories. The implications for patient care are profound as new treatments offer hope while industry players navigate complex regulatory and market environments. As these trends continue to unfold, they hold significant implications for future drug development processes and healthcare solutions worldwide. Thank you for tuning into Pharma Daily; we'll continue to bring you critical insights into this ever-evolving industry.Support the show
The FDA just expanded Mounjaro's label to include reducing the risk of major adverse cardiovascular events, and the headline is easy to love and easy to misunderstand. We slow it down and translate what the approval actually means for people living with type 2 diabetes, especially those worried about heart attack, stroke, and cardiovascular death.We unpack the exact endpoint behind the claim: MACE, which combines cardiovascular death, non-fatal heart attack, and non-fatal stroke, and we clarify what it is not saying (no, it is not “erasing plaque” or curing atherosclerotic cardiovascular disease). We also explain the real-world nuance around branding and indications: Mounjaro and Zepbound are both tirzepatide, but FDA labels are population-specific, and that can affect clinical decisions and insurance coverage.Then we walk through the Surpass-CVOT cardiovascular outcomes trial in plain English. The key twist is the comparator: tirzepatide was tested against Trulicity (dulaglutide), an active GLP-1 medication with known heart benefit, not placebo. That's why understanding noninferiority vs superiority matters so much. We talk hazard ratios, absolute vs relative risk, and the surprising finding that bigger weight loss and a larger A1C drop did not translate into statistically superior cardiovascular outcomes during the study window.We close with practical guidance and a list of questions you can bring to your own checkup, including whether you have established cardiovascular disease, what makes you “high risk,” whether other cardioprotective meds are already doing the job, how dose changes could affect insulin or blood pressure meds, and what it will actually cost. If you found this helpful, subscribe, share the show with someone managing diabetes risk, and leave us a review so more people can find clear medical context.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski
In today's episode, we spoke with Michael K. Wong, MD, PhD, FRPC. Dr Wong is a physician at Roswell Park Comprehensive Cancer Center in Buffalo, New York.In our exclusive interview, Dr Wong discussed the significance of the FDA's accelerated approval of vusolimogene oderparepvec-wtpg (Tudriqev; RP1) in combination with nivolumab (Opdivo) for adult patients with unresectable advanced cutaneous melanoma whose disease progressed on a prior PD-1–blocking antibody–based regimen. He noted that this approval followed a lengthy regulatory trajectory, including two prior complete response letters, before a third biologics license application was accepted in June 2026 and a positive advisory committee vote paved the way for approval.Dr Wong contextualized the evidentiary basis for the approval, drawing on data from the single-arm, phase 1/2 IGNYTE trial (NCT03767348), in which the efficacy-evaluable population achieved an objective response rate of 24.2% (95% CI, 15.8%-34.3%) and a median duration of response of 14.1 months (95% CI, 10.7-not reached). He emphasized that the trial enrolled a genuinely high-risk population, including patients with elevated lactate dehydrogenase, more than 55% with PD-L1–negative tumors by immunohistochemistry, 44% who had failed prior ipilimumab (Yervoy) plus nivolumab, and 66% with primary resistance to anti–PD-1 therapy, making the results clinically meaningful in the context of a setting where no robust options previously existed. He also addressed the distinction between RP1 and talimogene laherparepvec (Imlygic), the prior herpes-based oncolytic agent, explaining that RP1 is a fundamentally reengineered particle with distinct genetic modifications, enhanced oncolytic activity, and an expanded injection approach that includes visceral lesions such as those in the liver and lung. From an operational standpoint, Dr Wong outlined key considerations for community and academic practices looking to integrate RP1, including room setup, pharmacy handling of live agents, personal protective equipment protocols, and the importance of partnering with interventional radiology to inject a diversity of lesions across nodal basins for optimal response.Finally, Dr Wong positioned RP1 plus nivolumab within the broader post–PD-1 treatment landscape alongside tumor-infiltrating lymphocyte (TIL) therapy, noting that although both options now occupy this space, RP1 plus nivolumab offers a more broadly accessible treatment approach given the logistical demands of TIL therapy.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show
In today's episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Dr Lonial is a professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as chief medical officer at Winship Cancer Institute of Emory University in Atlanta, Georgia. In the exclusive interview, Dr Lonial discussed the significance of the first approval of a CELMoD-based therapy for patients with multiple myeloma, detailed the key findings from the phase 3 EXCALIBER-RRMM trial (NCT04975997) that supported the regulatory decision, and expanded on how this combination regimen fits into the early relapse treatment paradigm.
We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody. We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab. Key topics covered in this episode: Overview of the HERIZON-GEA-01 study and its findings Mechanism of action of zanidatamab Comparison of treatment regimens and overall survival benefits Management of side effects, including diarrhea and infusion reactions The role of PD-L1 testing in treatment decisions Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases! #GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers
What does a biotech CEO who has brought eight orphan drugs to market have in common with a bestselling novelist? In this case, they are the same person. Today's guest is Fredric Price, who writes award-winning fiction as David Hirshberg. His newest novel "Crossing the Bronx" completes a trilogy that began with "My Mother's Son" and continued with "Jacobo's Rainbow." Price is living proof that remarkable lives show up everywhere. He's been a CEO for decades, founded a biotech firm after he thought he had retired, is a book publisher, and only started writing fiction past middle age. In this conversation we talk about why storytelling is the real skill behind both raising millions for a drug and writing a novel, the unforgettable 30-second video he showed the FDA that changed everything, why he uses 1952 and 1955 to talk about 2026, and why he has no desire to write a pharma thriller. This is an episode about second acts, about never actually retiring, and about the idea that the technical details are just the skeleton — story is the muscle, flesh, and eyes.Get your copy of Crossing the Bronx by Fredric PriceAs an Amazon Associate, Now I've Heard Everything may earn a commission from qualifying purchases.Chapters:00:00 Introduction and Guest Background 01:51 Fredric Price's Diverse Career and Passions 05:00 The Skeleton and Flesh of a Good Story 07:41 Using History to Reflect the Present 11:11 Themes of Family and Rivalry in His Novels 13:24 Writing Without Being Handcuffed by History 14:45 Comparison of Satisfaction: Novels vs FDA Approval 16:13 Recognition and Success in Writing and Pharma 17:35 Future Projects and Reinventions 18:47 Closing Remarks and AppreciationGuest InformationFredric PriceWebsite1999 interview with Barry Gibbons For more intriguing and engaging interviews each week, subscribe now on:Spotify Apple Podcasts YouTube
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Join us as we dive into: The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide What makes cereblon modulators different from existing immunomodulatory agents (IMiDs) and their potential benefits The study design, findings, and the implications of minimal residual disease (MRD) as a primary endpoint for approval Who the ideal candidates for iberdomide are and how it fits into the current treatment landscape The side effect profile of iberdomide compared to traditional therapies and management strategies Insights on monitoring disease status and the future of cereblon modulators in combination with other therapies This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in multiple myeloma treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #CELMoDs, #MultipleMyeloma, #EXCALIBERstudy, #MRD, #OncologyBrothers
In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA. Intended for a US audience only. Sponsored by Outlook Therapeutics References 1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd 2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026. 3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next 4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective
The FDA has approved the first mRNA flu shot: Moderna's mFlusiva – but immunologist Dr. Jessica Rose says it safety tests are flawed. “… You will find the safety data that definitively shows that more people died in the context of the mRNA-1010 injectable product than in the comparator group,” writes Dr. Rose. “You should know that the comparator group ALSO were given a flu vaccine – NOT A SALINE PLACEBO.” Reuters reports the approval covers adults 50 and older, based on a late-stage trial of more than 40,000 people that showed the shot was 26.6% more effective than a licensed standard-dose flu vaccine. But Dr. Rose says that no saline placebo was used, and the comparator group also received a flu vaccine – and that the data she's seen indicates high adverse reactions to the new shots. Dr. Kelly Victory, Chief of Emergency & Disaster Medicine at The Wellness Company, joins Wellness Company CEO Peter Gillooly to discuss RFK's push to split the childhood MMR vaccine into separate shots, new releases from Dr. Fauci's pandemic text messages, and TWC's research on Alpha-Gal. Dr. Jessica Rose is a Canadian researcher with a Bachelor's in Applied Mathematics and a Master's in Immunology from Memorial University of Newfoundland. She holds a PhD in Computational Biology from Bar Ilan University and completed postdoctoral research in Molecular Biology and Biochemistry. Follow at https://jessicasuniverse.com Dr. Kelly Victory is Chief of Emergency & Disaster Medicine at The Wellness Company and a trauma and emergency specialist with over 30 years of experience. Follow at https://x.com/DrKellyVictory Peter Gillooly is CEO of The Wellness Company. Through the organization's initiatives and products, he promotes patient-first care and individual control over health decisions. Learn more at https://drdrew.com/twc 「 SUPPORT OUR SPONSORS 」 • BIOPRO - BioPro+® is a natural formula of growth factors and peptides that support how you look, feel & perform. Learn more at https://drdrew.com/biopro • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew • CHAPTER - For free and unbiased Medicare help, dial (218) 521-2472 to speak with my trusted partner, Chapter, or go to https://askchapter.org/drdrew Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan's contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don't directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - https://kalebnation.com • Susan Pinsky - https://x.com/firstladyoflove Content Producer • Emily Barsh - https://x.com/emilytvproducer Learn more about your ad choices. Visit megaphone.fm/adchoices
In today's episode, we spoke with Adam M. Brufsky, MD, PhD, about the FDA approval of gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for the treatment of adult patients with hormone receptor–positive, HER2-negative advanced breast cancer without a PIK3CA mutation following progression on or after treatment with 1 or more lines of endocrine therapy in the metastatic setting. Dr Brufsky is a professor of medicine and the associate division chief for the Division of Hematology/Oncology in the Department of Medicine at the University of Pittsburgh School of Medicine; as well as medical director of the Magee-Women's Cancer Program, associate director for clinical investigations, and codirector of the Comprehensive Breast Cancer Center at the University of Pittsburgh Medical Center Hillman Cancer Center, in Pennsylvania.In our exclusive interview, Dr Brufsky highlighted the significance of this approval, key efficacy and safety data from Study 1 of the phase 3 VIKTORIA-1 trial (NCT05501886) that supported this regulatory decision, and what the future may hold for metastatic breast cancer management strategies.
If you're holding off on stem cell therapy because you're waiting for FDA approval to bring the price down, this is the reality check you need.Dr. Joy Kong, a triple board certified physician and stem cell specialist at Chara Health, breaks down what FDA approved stem cell products actually cost. Cord blood transplants like Omidacel and AlloCord run $450,000 to $1.2 million. Ryoncil, used for pediatric graft versus host disease, totals $1.55 million. By comparison, current stem cell therapy provided as a legal tissue transplant, the same model used in organ transplants, costs $7,000 to $25,000 per infusion.Dr. Joy explains why that gap exists, and what it means if you're counting on insurance to make this treatment affordable.✨ Learn more about how to live a long and pain-free life: https://joykongmd.com/Dr. Joy talks about:0:21 Why FDA Approval Doesn't Lower Cost2:26 Cost Of FDA-Approved Stem Cell Products3:40 Why Legal Stem Cell Therapy Is CheaperAdditional ResourcesVisit My Clinic: Chara Health
Samsung’s Galaxy Buds Hearing Aid feature gains US FDA approval to launch later in 2026, Foxconn reveals AI servers bring in 51% of revenue with Apple manufacturing dropping to under 30%, and OpenAI releases a ChatGPT desktop app for Linux. MP3 Please SUBSCRIBE HERE for free or get DTNS shows ad-free. A special thanks toContinue reading "Samsung Galaxy Buds Hearing Aid Feature Receives FDA Approval – DTH"
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of pivotal advancements that underscore the dynamic nature of our industry. Starting with Moderna, which has recently secured FDA approval for its mRNA-based influenza vaccine, MFLUSIVA. This marks a monumental leap in leveraging mRNA technology beyond its initial role in COVID-19 vaccine development. The approval not only highlights the technology's adaptability and efficiency but also hints at a transformative future for seasonal vaccines, potentially allowing for rapid responses to influenza virus mutations. In tandem with this development, Takeda has achieved FDA approval for Orzeyful (Oveporexton), an innovative therapy targeting narcolepsy type 1. This represents a significant breakthrough as it targets the root cause of the disorder through orexin receptor modulation. The implication here is profound—offering new hope for patients who have long been underserved by existing treatments and potentially setting a new standard in managing sleep disorders. On the leadership front, Sarepta Therapeutics welcomes new CEO Michael Severino during a critical growth phase. Known for its focus on rare diseases, Sarepta faces the challenge of maintaining its competitive edge and meeting stakeholder expectations in a rapidly evolving market landscape. Meanwhile, AstraZeneca and CSPC Pharmaceutical are enhancing their manufacturing capabilities through a joint venture aimed at bolstering biologics production in China—a strategic move that positions them well within one of the fastest-growing markets for such treatments. This partnership is expected to accelerate the availability of biologic therapies across Asia. In another significant leadership change, Fujifilm Biotechnologies appoints Maja Pedersen as president, signaling a strategic shift towards strengthening its contract development and manufacturing organization operations. This move is reflective of broader industry trends emphasizing operational efficiency and strategic restructuring amid changing market demands. Elsewhere, Emergent BioSolutions has eliminated its top R&D role as part of sweeping restructuring efforts. This decision underscores ongoing challenges companies face in balancing innovation with operational efficiency amidst market pressures. In legal arenas, Galderma Laboratories emerged victorious over Sanofi regarding claims made about its blockbuster drug Dupixent. This victory highlights the importance of substantiating promotional claims in an increasingly competitive pharmaceutical marketing landscape. Turning to clinical trials, Biovie's recent study on Parkinson's disease has sparked debate due to its emphasis on composite endpoints rather than primary ones. While offering insights into specific patient subgroups, this approach raises questions about trial design and result interpretation—a critical factor for drug development success. Investment activities are also shaping industry trends significantly. Notably, Lifemine Therapeutics has secured substantial funding from high-profile investors like Bill Gates and Jeff Bezos. This investment reflects burgeoning interest in innovative biotech platforms capable of addressing complex diseases through unique mechanisms. Moreover, Icon's collaboration with Anthropics aims to integrate AI into clinical trials—an exciting development poised to streamline these processes significantly. By leveraging artificial intelligence capabilities, this partnership could accelerate drug development timelines and improve trial outcomes. Overall, these developments highlight transformative changes within the pharmaceutical and biotech sectors. Innovative therapeutics, strategic partnerships, leadership transitions, regulatory milestones, and technological advancements collectively drive significant progress in patient care and drug development. As we navigate these changes, it's crucial for industry stakeholders to capitalize on emerging opportunities while addressing associated challenges such as regulatory compliance, market competition, and operational efficiencies. Thank you for tuning into Pharma Daily—stay informed and stay ahead!Support the show
New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. Presenters: Sara A. Hurvitz, MD, FACP Professor of Medicine Smith Family Endowed Chair in Women's Health Senior Vice President, Clinical Research Division Fred Hutch Cancer Center Head, Division of Hematology/Oncology, Department of Medicine University of Washington School of Medicine Seattle, Washington Shanu Modi, MD Section Head, HER2 Breast Program Professor and Attending Member Breast Medicine Service, Department of Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Link to full program: https://bit.ly/4z1Xb6a Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The ALL ME® Podcast Peptides: What You Need to Know About This Growing Trend – Dr. Brandon Welch In this episode, Dr. Brandon Welch discusses the complex world of peptides, their uses, risks, and the regulatory landscape, providing valuable insights for athletes, parents, and young enthusiasts. Takeaways: What are peptides and how do they work? Regulatory status of peptides: FDA approval and bans Risks and side effects of peptide use Sources and quality concerns of online peptides The rise of peptides in social media and biohacking Clinical trials and safety data for peptides Legal considerations for prescribing and dispensing Impact of peptides on health and performance Chapters: 00:00 Introduction to Peptides and Their Importance 03:02 Dr. Brandon Welch's Journey into Pharmacy 05:40 Understanding Peptides: The Basics 08:52 Peptides: Legal Status and Safety Concerns 11:26 Research-Only Peptides: Risks and Regulations 14:22 The Role of Influencers in Peptide Popularity 17:19 The Surge of Peptides in Recent Years 20:05 Popular Peptides: Reta TrueTide and BPC157 34:12 Injectable Drugs and Athletic Recovery 37:49 The Risks of Peptides and Tumor Growth 38:40 CJC-1295: Benefits and Risks 42:57 Ipamorelin: Understanding Its Use and Risks 46:03 Dependency on Growth Hormones 48:27 TB500: Potential and Limitations 50:09 The Push for FDA Approval of Peptides 56:06 Advice for Young Athletes on Peptide Use Resources: · https://sportsrxnetwork.com/ · https://www.usada.org/ · https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information · https://clinicaltrials.gov/ Follow Us: Twitter: @theTHF Instagram: @theTHF Facebook: Taylor Hooton Foundation #ALLMEPEDFREE Contact Us: Twitter: @theTHF Instagram: @theTHF Facebook: Taylor Hooton Foundation #ALLMEPEDFREE Email: info@taylorhooton.org Phone: 214-449-1990 ALL ME Assembly Programs: http://taylorhooton.org/education-resources/face-to-face-programs/
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By combining their resources, the new entity is expected to enhance its capabilities in neurological disorders with a robust portfolio of approved drugs. This merger allows the companies to leverage economies of scale, optimize research and development, and expand their market presence, offering promising prospects for advancements in treating CNS-related conditions. In regulatory news, Novartis has secured FDA approval for an expanded indication of Pluvicto (lutetium vipivotide tetraxetan), a radioligand therapy originally approved for PSMA-positive metastatic castration-resistant prostate cancer. This therapy can now be used for metastatic hormone-sensitive prostate cancer, marking a significant step forward in prostate cancer treatment. By targeting prostate-specific membrane antigen (PSMA) with precision, Pluvicto offers the potential for improved patient outcomes and highlights the growing role of radioligand therapies in oncology. Globally, Pharmamar's Zepzelca (lurbinectedin) has been approved in Canada, Qatar, and South Korea as a first-line maintenance therapy for extensive-stage small cell lung cancer. This approval signifies a potential shift in how aggressive cancer types are treated, particularly when combined with PD-L1 inhibitors, opening new avenues for effective combination therapies. Industry partnerships continue to drive innovation, as seen with Fujifilm and Taiho Pharmaceutical's collaboration to develop next-generation antibody-drug conjugate (ADC) manufacturing technologies using the Aralinq platform. With ADCs becoming increasingly pivotal in targeted cancer therapies due to their precision in delivering cytotoxic drugs to tumor cells, advancements in manufacturing could significantly enhance production capabilities and therapeutic efficacy. Financial dynamics within the industry remain robust. AbbVie has raised its 2026 revenue forecast to $67.6 billion, citing strong performances from its immunology drugs Skyrizi and Rinvoq. These therapies have shown substantial success in treating autoimmune conditions, reflecting their impact on AbbVie's financial health and reinforcing confidence in their commercial viability. On the clinical trial front, Ratio Therapeutics has successfully closed a $70 million Series C funding round to support its radiotherapeutics pipeline and initiate the ATLAS trial. This infusion of funds underscores the continued interest and investment in radiopharmaceuticals with promising applications in oncology. The landscape of mergers and acquisitions remains active as AstraZeneca and Bristol Myers Squibb reportedly engage in early-stage merger discussions. Such a merger could create an oncology giant valued at approximately $400 billion, potentially reshaping competitive dynamics and accelerating innovation across therapeutic areas. Regulatory changes are also underway with HRSA advancing a revised 340B rebate model pilot program despite hospital opposition. The implications for healthcare providers are significant as this could affect operational efficiencies and financial strategies within participating entities. Overall, these developments reflect ongoing trends toward industry consolidation and strategic partnerships that foster innovation in drug manufacturing technologies. Regulatory approvals continue to advance precision medicine through targeted therapies, showcasing the sector's dynamic nature as it addresses unmet medical needs while navigating complex regulatory environments. Meanwhile, Sandoz's settlement of nearly $500 million for antitrust claims in the U.S. highlights ongoing scrutiny of industry competition practices. This settlement signals potential shifts in market dynamics as companies seek to resolve legal challenges while maintaining operational integrity. Cybersecurity has emerged as a critical concern following Amgen's reported breach compromising sensitive patient data. This incident amplifies the need for enhanced data protection measures to safeguard information integral to patient trust and competitive integrity. In leadership news, BioNTech has appointed Guido Oelkers as CEO amid its continued innovation in mRNA technology post-COVID-19. This strategic move underscores BioNTech's commitment to leadership capable of navigating advances in mRNA therapeutics. Lastly, Novo Nordisk faced setbacks with its investigational therapy ziltivekimab failing a phase 3 trial targeting inflammatory pathways for cardiovascular outcomes. Despite such challenges, these high-stakes trials highlight both risks and opportunities inherent in pharmaceutical innovation. As we reflect on these stories, it's clear that scientific advancements, regulatory developments, and strategic business moves continue to shape the trajectory of the pharmaceutical and biotech sectors. These efforts promise significant implications for future drug development and patient care as companies strive to harness breakthroughs while adapting to evolving industry landscapes.Support the show
In today's episode, we welcomed Douglas W. Sborov, MD, MS, to discuss the significance of the July 2026 FDA approval of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications. Dr Sborov is a tenured professor of medicine in the Department of Internal Medicine in the Division of Hematology and Hematologic Malignancies and an adjunct associate professor in the Departments of Molecular Pharmaceutics and Biomedical Engineering at the University of Utah Huntsman Cancer Institute (HCI) in Salt Lake City, as well as director of the HCI Hematology Disease Center and Plasma Cell Dyscrasias (PCD) Program, co-leader of the Hematologic Malignancies Clinical Trials Research Group, and member of the HCI Experimental Therapeutics Program and International Myeloma Working Group (IMWG).As part of the July 10, 2026, approval, subcutaneous isatuximab is indicated for use: in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide (Revlimid) and a proteasome inhibitor in combination with carfilzomib (Kyprolis) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy in combination with bortezomib (Velcade), lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for an autologous stem cell transplant In our exclusive interview, Dr Sborov outlined how the subcutaneous formulation of isatuximab and the ability to administer the agent via an on-body delivery system could affect patient quality of life. He also detailed key findings from the phase 3 IRAKLIA trial (NCT05405166) that supported the approval and explained how the use of isatuximab may shift in clinical practice following the subcutaneous approval.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the latest news shaping these dynamic sectors, exploring strategic corporate maneuvers, groundbreaking scientific advances, and pivotal regulatory changes. GlaxoSmithKline (GSK) is embarking on a comprehensive restructuring initiative aimed at achieving $2.5 billion in annual cost savings by 2029. This ambitious initiative underscores the company's commitment to strengthening its late-stage research and development capabilities. The strategy involves optimizing mature product lines, procurement processes, and supply chain efficiencies, reflecting broader industry trends where financial prudence is balanced with innovation. As part of this transformation, GSK plans to relocate its research headquarters near AstraZeneca's facilities, though specifics on employment impacts remain under wraps. This restructuring highlights the competitive nature of the pharmaceutical landscape and GSK's intent to maintain its edge through enhanced R&D initiatives. Meanwhile, Johnson & Johnson is nearing a resolution in its extensive talc litigation by proposing a $5.5 billion settlement to resolve approximately 76,000 lawsuits. These lawsuits allege that J&J's talc-based baby powder caused ovarian cancer. This potential settlement represents a significant step toward closing a protracted chapter of legal scrutiny for J&J, offering the company a chance to mitigate ongoing legal risks and refocus on core business operations. On the regulatory front, MannKind has secured FDA approval for its fast-acting edema autoinjector, reflecting an ongoing emphasis on addressing unmet medical needs with innovative delivery mechanisms. Conversely, Baxter has issued a recall for one lot of cefazolin in dextrose injection due to contamination concerns, underscoring the continuous challenges of ensuring product safety within complex manufacturing and supply chain environments. In terms of public health initiatives, Gilead Sciences is employing a novel approach to HIV prevention through its "Up to Date" campaign featuring comedians Nicole Byer and Devon Walker. This effort aims to destigmatize HIV discussions within the Black community by leveraging humor and relatability—a testament to evolving strategies in patient engagement and education. In drug development news, Atea Pharmaceuticals is making strides with its hepatitis C treatment candidate following positive Phase 3 trial results showing equivalence with Gilead's Epclusa. This positions Atea for further clinical evaluations and potential market entry with a simplified treatment regimen. Similarly, Hansoh Pharmaceutical's collaboration with GSK has yielded another Phase 3 success for their B7-H3-directed antibody-drug conjugate in China, highlighting the growing importance of targeted therapies in oncology. Emerging biotech hubs are reshaping the industry's landscape as cities beyond traditional centers like Boston and San Francisco gain prominence. This geographical diversification reflects global trends in biotech innovation and investment. In clinical advancements, Altimmune's GLP-1/glucagon receptor-targeting drug shows promise in reducing heavy drinking among individuals with alcohol use disorder (AUD). This finding opens new therapeutic avenues for AUD by leveraging mechanisms traditionally associated with weight loss medications. Concurrently, regulatory scrutiny remains high as Replimune faces setbacks with its melanoma data package deemed "not interpretable" by the FDA—an indication of the rigorous standards required for gaining regulatory approval. The geopolitical landscape also influences industry dynamics, particularly in China where intellectual property risks are heightened under new legislative acts. Companies must navigate these complexities strategically to protect innovations while capitalizing on market opportunities. Financially, Novo Holdings-backed Claris has secured $118 million in Series B funding to advance its corneal disease drug candidate—a substantial investment underscoring growing interest in ophthalmology therapeutics. Additionally, RA Capital has launched Oak Hill Bio onto Nasdaq via a special purpose acquisition company (SPAC), focusing on rare genetic diseases—a strategy showcasing continued momentum within biotech to leverage financial tools for niche therapeutic advancements. Overall, these developments reflect an industry characterized by rapid scientific progress and evolving regulatory landscapes. Companies are under pressure to optimize operations while ensuring robust clinical data to meet regulatory standards. As these sectors strive for innovation and patient care advancements amidst competitive global markets, balancing innovation with safety and efficacy remains paramount. As always, we'll continue to track these stories closely and bring you the latest insights right here on Pharma Daily.Support the show
In today's episode, we spoke with Jorge E. Cortes, MD, and Elias Jabbour, MD. Dr Cortes is the chief of Hematology in the Division of Hematology and Oncology and the associate director for Translation at the UAB O'Neal Cancer Center in Birmingham, Alabama. Dr Jabbour is a professor of leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.In our exclusive interview, Dr Cortes and Dr Jabbour discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, they both discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, the two also shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm.
In today's episode, we spoke with Sara M. Tolaney, MD, MPH, about the FDA approval of sacituzumab govitecan plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA-authorized test. Dr Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston, Massachusetts.This regulatory decision was backed by findings from the phase 3 ASCENT-04/KEYNOTE-D19 trial (NCT05382286), in which the median progression-free survival among patients in the sacituzumab govitecan arm was 11.2 months (95% CI, 9.3-16.7) vs 7.8 months (95% CI, 7.3-9.3) among patients who received physician's choice of chemotherapy plus pembrolizumab (HR, 0.65; 95% CI, 0.51-0.84; P = .0009).In our exclusive interview, Dr Tolaney highlighted the significance of this approval, key data from ASCENT-04, and how the TNBC paradigm is shifting to accommodate this new regimen.
In today's episode, we welcomed Everett Meyer, MD, PhD, an associate professor of medicine (blood & marrow transplantation), an associate professor of pediatrics (stem cell transplantation), and an associate professor of surgery (abdominal transplantation) at Stanford Medicine in California.In the exclusive interview, Dr Meyer discussed the significance of the June 2026 FDA approval of allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution, and to improve chronic graft-vs-host disease (cGHVD)–free survival in the treatment of adults with hematological malignancies. Dr Meyer also broke down what the approval of Orca-T means for the transplant field, detailed the design and key outcomes from the phase 3 Precision-T trial (NCT05316701) that supported the approval, and outlined how this approach could be integrated into clinical practice.
Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer. Guests: Alexander Drilon, MD Chief, Early Drug Development Service Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Rosario Charo Garcia Campelo, MD Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain
390: Lab grown meat is now officially approved in the U.S., and in this Bite of Knowledge, I'm breaking down exactly what that means for you. I'll explain how cultivated meat is made, why several states are pushing back with bans, and why labeling these products is still so confusing. I'll also share the major companies producing lab grown meat, discuss the claims around sustainability, and dive into the potential health concerns and safety questions that still remain. If you've been wondering whether lab grown meat is already making its way onto grocery store shelves and how to identify it, this episode will give you the information you need to make informed choices. Topics Discussed: → What is Lab-Grown Meat → How to Spot Lab-Grown Meat → Lab-Grown Meat Labels → Lab-Grown Meat Companies → Lab-Grown Meat Risks As always, if you have any questions for the show please email us at digestthispod@gmail.com. And if you like this show, please share it, rate it, review it and subscribe to it on your favorite podcast app. Sponsored By: → Bethany's Pantry | Go to https://bethanyspantry.com/ and use code PODCAST10 for $10 anything! → Manukora | Head to https://manukora.com/DIGEST to save up to 31% plus $25 worth of free gifts with the Starter Kit, which comes with an MGO 850+ Manuka Honey jar, 5 honey travel sticks, a wooden spoon, and a guidebook! Timestamps: → 00:00:00 - Introduction → 00:00:16 - Lab-Grown Meat Is Now Approved → 00:04:00 - FDA Approval & State Bans Explained → 00:05:28 - Which States Ban Lab-Grown Meat? → 00:05:42 - How to Spot Lab-Grown Meat Labels → 00:07:56 - Is Lab-Grown Meat Better for the Environment? → 00:09:48 - Health Risks & Safety Concerns → 00:15:00 - Companies Producing Lab-Grown Meat → 00:20:32 - Should You Be Concerned?Further Listening: → Lab Grown Meat, Meat Glue, & Mixing Different Animals To Create 80/20 Ground Meat | Will Harris Check Out Bethany: → Bethany's Instagram: @lilsipper → YouTube → Bethany's Website → Discounts & My Favorite Products → My Digestive Support Protein Powder → Gut Reset Book → Get my Newsletters (Friday Finds) Learn more about your ad choices. Visit megaphone.fm/adchoices
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show
What if curing a disease took a single treatment instead of a lifetime of pills, and the same technology could help cool the planet? In this episode, Dr. Bradley Ringeisen, Executive Director of the Innovative Genomics Institute (IGI) at UC Berkeley, takes us inside the CRISPR revolution. From the first FDA-approved sickle cell therapy to a custom cure that saved a baby's life in Philadelphia, to rice engineered to emit 60% less methane, Brad reveals how genome editing is reshaping medicine, climate, and food security alike. We dig into the science, the make-or-break "delivery" challenge, and the IGI's "CRISPR Commons" initiative, a bold plan to make genome editing equitably accessible worldwide.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show
Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for untreated classical Hodgkin lymphoma.
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials. Key topics covered in this episode include: Overview of the recent FDA approvals for antibody-drug conjugates (ADCs) in breast cancer Detailed discussion on the ASCENT-04 trial focusing on PD-L1–positive metastatic triple-negative breast cancer Insights into the ASCENT-03 trial for PD-L1–negative disease Comparison of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), including their efficacy and side effect profiles Management strategies for common side effects such as neutropenia and diarrhea Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explored the evolving landscape of breast cancer treatment and the importance of shared decision-making in patient care. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wave of exciting advancements and strategic movements shaping the landscape of this ever-evolving industry. Starting with a significant breakthrough in cell therapy, the FDA has granted approval to Orca Bio's Tregzi, a novel treatment aimed at preventing graft-versus-host disease (GVHD) in blood cancer patients undergoing allogeneic transplants. This approval emphasizes the potential of regulatory T cells in mitigating the severe complications that often accompany such transplants. The success of Tregzi not only marks a pivotal moment for cell therapy but also heralds a new era in transplant medicine where cellular therapies can significantly improve patient outcomes by reducing GVHD incidence. In other strategic moves, Ipsen's acquisition of Memo Therapeutics for up to $796 million highlights the industry's focus on addressing unmet needs in transplant medicine. Memo's work on monoclonal antibodies targeting the BK virus—a significant threat to kidney transplant patients—reflects a growing trend towards personalized medicine and targeted biologics. This acquisition is poised to bring much-needed therapeutic interventions to market, underscoring the sector's commitment to innovative solutions. Meanwhile, Anthropic is making waves with the introduction of Claude Science AI Workbench, accompanied by an internal drug discovery program aimed at neglected diseases. This initiative underscores the transformative role of artificial intelligence in drug discovery, particularly in areas previously overlooked due to limited commercial incentives. By accelerating the identification and development of novel therapeutics, AI-driven platforms promise breakthroughs in treating rare and neglected diseases. In clinical trial news, Abivax has reported promising Phase 3 safety data for obefazimod, a miR-124 enhancer targeting ulcerative colitis. By alleviating previous cancer-related concerns, obefazimod stands out as a potential small molecule oral therapy for autoimmune conditions. This advancement demonstrates ongoing innovation in small molecule therapeutics designed to modulate immune responses, expanding treatment options for ulcerative colitis patients. On the financial front, several companies are bolstering their pipelines through significant funding efforts. Alvotech has secured a $75 million term loan to enhance its biosimilar pipeline, reflecting the increasing importance of cost-effective biologic alternatives. AB Science has raised approximately $2.62 million focusing on oncology and rare diseases like acute myeloid leukemia (AML) and amyotrophic lateral sclerosis (ALS). Additionally, Flare Therapeutics' $85 million Series C round emphasizes precision medicine approaches targeting transcription factors, illustrating the industry's dedication to precision medicine. Regulatory landscapes are also shifting with Sarepta Therapeutics' FDA acceptance for full approval bids on Amondys 45 and Vyondys 53 despite confirmatory trial challenges. These therapies leverage exon skipping technology for Duchenne muscular dystrophy treatment, highlighting the intricate balance between accelerated approvals and robust clinical evidence requirements. In mergers and acquisitions news, Kimball Electronics' acquisition of Helvoet Polymer Technologies expands their drug delivery systems capabilities across Europe and India. This strategic alignment reflects broader industry trends towards integrated service offerings and global expansion efforts. Regulatory challenges continue with leadership changes at the FDA as Vijay Kumar steps down amid ongoing turbulence within gene and cell therapy sectors. Additionally, Angitia Biopharmaceuticals' termination of its Phase 3 trial for its BMP-6 candidate illustrates inherent risks and strategic pivots often necessary in drug development. Turning our focus globally, China's approval of its first CAR-T therapy for solid tumors signals a pivotal moment in oncology. This milestone could spur similar advancements worldwide, particularly drawing interest on when such treatments might receive approval in other regions like the United States. Moderna's expansion into in vivo CAR-T therapies for autoimmune diseases further marks a strategic divergence from traditional approaches, aiming to create off-the-shelf solutions that redefine treatment paradigms. Gene therapy continues to gain traction as Uniqure navigates regulatory reversals from the FDA regarding its Huntington's disease gene therapy filing for accelerated approval. This development hints at a broader shift within regulatory bodies towards fostering innovation in rare disease treatments under new leadership directives. Industry-wide trends also reveal a notable shift towards automation in cell therapy production led by companies like Cellares and Ori. This reflects growing demands for scalable manufacturing processes that enhance production capabilities while reducing costs. Overall, these developments illustrate a dynamic landscape where scientific innovations, strategic partnerships, regulatory adjustments, and technological integrations drive progress across various medical fields. As these sectors evolve, they hold vast potential for transforming patient care through groundbreaking therapeutic options and improved healthcare delivery systems worldwide.Support the show
In today's episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.
Welcome to a special edition of IDEA Collider's "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data. Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the "psychedelic experience" is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety. Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems. Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Athina Metaxa; LinkedIn: https://www.linkedin.com/in/athina-marina-metaxa/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/
A short while ago, we shared very positive results from the Phase 3 clinical trials for fenebrutinib in both relapsing-remitting and primary progressive MS. Those results have been submitted to the FDA for approval. This week, Dr. Jiwon Oh, the principal investigator in one of the Phase 3 trials for fenebrutinib, walks us through these positive results and explains what makes fenebrutinib a different kind of disease-modifying therapy and who might benefit most from it. We're also talking about the European approval of Cenrifki (Tolebrutinib) to treat nonrelapsing secondary progressive MS, and we'll share our perspective on why the FDA should have -- and should still -- approve this DMT in the U.S. We'll tell you about two studies funded by the National MS Society that will focus on identifying links between menopause and MS. We'll share some sobering news about healthcare affordability in America. And we'll share some good news from the U.S. House Appropriations Committee, along with an opportunity for you to spend just 5 minutes doing some important advocacy work. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Fenebrutinib has been submitted to the FDA for approval :22 Cenrifki (Tolebrutinib) approved in Europe for Nonrelapsing Secondary Progressive MS 1:09 National MS Society funds two studies to identify links between menopause and MS 4:19 Healthcare has become unaffordable for the majority of Americans 8:23 The U.S. House Appropriations Committee has approved $20 million in funding for the MS Research Program 11:57 Dr. Jiwon Oh explains why Fenebrutinib is a different kind of disease-modifying therapy, and who may benefit from it 15:36 Share this episode 32:22 Next week 32:43 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/461 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com PHASE 3 CLINICAL TRIAL: Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis https://www.nejm.org/doi/abs/10.1056/NEJMoa2415988 VIDEO: Principal Investigator Dr. Robert Fox Discusses the Phase 3 clinical trial for Tolebrutinib in Nonrelapsing Secondary Progressive MS https://www.youtube.com/watch?v=tJQ93qdlXrU GALLUP POLL: U.S. Adults' Ability to Afford Healthcare at a Five-Year Low https://news.gallup.com/poll/710942/adults-ability-afford-healthcare-five-year-low.aspx JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 461 Guest: Dr. Jiwon Oh Privacy Policy
In today's episode, we spoke with Courtney D. DiNardo, MD, MSCE, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and an associate member of The University of Texas Graduate School of Biomedical Sciences in Houston.In our exclusive interview, Dr DiNardo discussed the May 2026 FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). DiNardo outlined numerous important facets of the approval, including its effects on the treatment paradigm, which patients will benefit most, safety considerations with the regimen, and quality of life advantages that have been observed with the combination. Furthermore, she discussed how this approval fits into a larger shift for the AML treatment paradigm and how the AML research field can build upon the approval of this regimen.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of this dynamic industry. Replimune has made headlines with the resubmission of its oncolytic virus-based immunotherapy, RP1, to the U.S. Food and Drug Administration for treating advanced melanoma. The FDA's acceptance after two prior rejections is significant, suggesting a shifting regulatory landscape that could favor innovative cancer therapies like oncolytic viruses. These therapies represent a novel approach to engage the immune system in targeting tumors, and if RP1 gains approval, it may open doors for similar treatments, potentially offering new hope for melanoma patients. On the regulatory side, Amgen has encountered challenges with Tavneos after losing European Union endorsement due to data integrity issues. This serves as a stark reminder of the critical importance of maintaining stringent data management throughout drug development. With an FDA hearing on the horizon, the implications are far-reaching, emphasizing increased scrutiny from regulatory bodies worldwide. This scenario could lead to more rigorous guidelines governing data practices in the future. The European Commission's approval of Henlius' Hetronifly as a first-line treatment for squamous non-small cell lung cancer marks a milestone in cancer immunotherapy. This approval highlights the ongoing efforts to improve patient outcomes through innovative PD-1 inhibitor-based combination therapies, showcasing progress in the fight against one of the most challenging forms of cancer. Epicrispr Biotechnologies brings promising news from its phase 1/2 trial of EPI-321, a gene therapy for facioscapulohumeral muscular dystrophy. The trial's success in enhancing muscle function through epigenetic silencing underscores significant advancements in gene therapy applications for neurological disorders. Similarly, Abbisko Therapeutics' phase 2 trial reports a 90% objective response rate using FGFR2/3 and PD-L1 inhibitors for gastric cancer, demonstrating the potential of targeted small molecule therapies in oncology. In financial developments, Definium Therapeutics and Ligachem Biosciences have made substantial funding strides to bolster their drug development pipelines. Definium's $805 million raise aims to advance psychiatric and neurological treatments, while Ligachem's funding will enhance its antibody-drug conjugate platforms. These investments reflect strong investor confidence in next-generation therapeutic platforms and underscore innovative financing strategies crucial for sustaining research and development efforts. Bayer's recent legal victory at the Supreme Court overturning a $1.25 million verdict related to its Roundup product is another focal point. This ruling not only positively impacts Bayer's financial standing but also highlights the complexities surrounding product liability cases within pharmaceuticals and agrochemicals. Strategically, Moderna has unveiled an ambitious R&D roadmap aiming for break-even by 2028 with over seven new products on the horizon. By focusing on mRNA vaccines for oncology and rare diseases, Moderna continues to leverage its technology beyond COVID-19 applications, potentially transforming treatment paradigms across various therapeutic areas. Shifting focus to industry trends, Sanofi finds itself under investigation by the European Commission for antitrust violations linked to its flu vaccine marketing practices. This situation underscores growing scrutiny over competitive practices within the pharmaceutical sector and could influence regulatory compliance strategies across global markets. In technological advancements, Eli Lilly is employing artificial intelligence to raise awareness about Alzheimer's disease through creative engagements like a European radio show road trip. These initiatives reflect an industry-wide shift towards technology-driven marketing strategies aimed at personalizing patient interactions. Lastly, Merck KGaA's $11 billion acquisition of Bio-Techne exemplifies a strategic move to enhance capabilities in immune cell therapy production. This deal underscores the growing importance of manufacturing innovations in bringing advanced therapies to market and highlights strategic collaborations increasingly seen across the sector. The landscape is further defined by significant scientific breakthroughs such as Revolution Medicines' development of a second RAS blocker, showing improved chemotherapy responses in pancreatic cancer patients. These advancements underscore the need for continued investment in targeted therapeutics research as they promise better patient outcomes and highlight ongoing innovation within oncology. As these developments unfold, they reflect an industry poised for transformation amid evolving scientific, regulatory, and market dynamics aimed at improving patient care globally. With these insights into current trends and future directions, it's clear that the pharmaceutical and biotech sectors are navigating a period rich with potential for groundbreaking advancements that will shape healthcare outcomes worldwide.Support the show
In today's episode, we spoke with Michael J. Mauro, MD, an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.In our exclusive interview, Dr Mauro discussed the orally disintegrating tablet formulation of nilotinib (Cavhanza) and its recent June 2026 FDA approval for patients with chronic myeloid leukemia (CML). After diving into the approval itself and the data that supported it, Mauro discussed why the approval is significant and which patients it will benefit most. In addition to covering the approval, Mauro shed light on what is to come for biosimilars and alternate formulations in the greater CML treatment paradigm.
Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.
What if the biggest issues in dentistry are the ones you can't see? In this episode of the Raving Patients Podcast, Dr. Len Tau sits down with renowned prosthodontist and innovator Cherilyn Sheets to discuss how new diagnostic technology is changing the future of dentistry. Cherilyn shares the story behind Interview and Quantitative Percussion Diagnostics (QPD), a science-based system designed to detect cracks, loose restorations, implant instability, and structural weaknesses before they become catastrophic problems. Dr. Tau and Cherilyn explore how this technology helps dentists improve diagnostics, increase patient trust, and boost case acceptance by showing patients issues that traditional imaging often misses. They also dive into the intersection of dentistry, engineering, AI, and preventive care, along with the journey of bringing a groundbreaking dental innovation to market. From early diagnosis to patient communication, this conversation highlights how modern dentistry is moving beyond what can simply be seen on an X-ray. What You'll Learn How Quantitative Percussion Diagnostics (QPD) works Why traditional imaging can miss structural tooth problems How Interview technology helps improve case acceptance The role of AI and engineering in modern dental diagnostics How dentists can identify cracks, loose crowns, and implant instability earlier Why preventive intervention creates better patient outcomes How Cherilyn Sheets helped develop and commercialize this technology The importance of combining science, integrity, and innovation in dentistry — Key Takeaways 00:56 Introduction to Cherilyn Sheets and Interview Technology 03:30 What Interview Technology Actually Does 06:11 Who Benefits Most from QPD Diagnostics 08:42 How Technology Improves Case Acceptance 11:10 Understanding Quantitative Percussion Diagnostics (QPD) 14:52 Detecting Cracks, Stress, and Structural Problems Early 17:55 Comparing Interview to Other Diagnostic Technologies 18:35 Using QPD to Find Pain Sources Faster 19:16 Common Objections and Ease of Use in Practices 23:22 FDA Approval and Product Validation 25:29 The Story Behind the Technology's Creation 30:55 Why Interview Complements X-Rays Instead of Replacing Them 32:42 Cherilyn's Passion for Innovation and AI in Dentistry 33:45 Lightning Round Questions 40:30 Special Offer and How to Learn More About Interview 41:40 Final Thoughts and Episode Wrap-Up — Connect with Cherilyn Website: Innerview AI - https://innerview.ai/ Email: cgsheets@ncofi.org Organization: Newport Coast Oral Facial Institute (NCOFI) — Learn proven dental marketing strategies and online reputation management techniques at DrLenTau.com. This podcast is sponsored by Dental Intelligence. Learn more here. This podcast is sponsored by CallRail, call tracking & lead conversion software for dentists. Find out more here. Raving Patients Podcast is your go-to place for the latest and best dental marketing strategies that will help you skyrocket your practice. Follow us for more!
A Place Called Hope: Dr. Francisco Contreras on Cancer Care, Faith, and Integrative Healing Episode Description In this episode of Conversations with a Chiropractor, Dr. Stephanie Wautier sits down with Dr. Francisco Contreras of Oasis of Hope in Tijuana, Mexico, for a thoughtful and deeply meaningful conversation about cancer care, hope, faith, prevention, and whole-person healing. Dr. Contreras shares the story of Oasis of Hope, founded by his father, Dr. Ernesto Contreras, more than 60 years ago. What began as a vision to care for the physical, emotional, and spiritual needs of cancer patients has grown into an international integrative oncology center serving patients from around the world. Stephanie and Dr. Contreras talk about the importance of treating the whole person, not just the diagnosis. Their conversation moves through integrative cancer care, immune support, natural and conventional treatment options, nutrition, exercise, stress, spiritual strength, early detection, breast cancer screening, biopsy concerns, and the role of hope in the healing process. Dr. Contreras also discusses why he believes patients need clear, understandable information when facing cancer. With so much information online, the process can feel overwhelming and frightening. His message is steady and compassionate: cancer is serious, but it does not have to immediately steal a person's joy, clarity, or hope. This episode includes discussion of cancer treatment, prevention, screening, integrative oncology, COVID vaccination concerns, and medical decision-making. It is meant to inform, encourage, and spark deeper questions, not replace personal medical advice. Anyone dealing with cancer, screening decisions, treatment options, supplements, or major health changes should work directly with a qualified medical team that understands their individual situation. In This Episode, Discover The story behind Oasis of Hope and its 60-year history How Dr. Ernesto Contreras helped shape a whole-person approach to cancer care Why Dr. Francisco Contreras believes emotional and spiritual support matter in healing What integrative oncology means at Oasis of Hope Why some natural therapies are studied but not widely approved or adopted How immunotherapy and immune support fit into the Oasis of Hope approach Dr. Contreras' perspective on rising cancer rates in younger people Simple lifestyle steps that may help reduce cancer risk The importance of fruits, vegetables, movement, stress reduction, and spiritual strength Why cancer symptoms often appear after disease is already present Mammograms, ultrasound, MRI, thermography, and early detection How Dr. Contreras thinks about biopsy risk versus diagnostic benefit When someone might consider contacting Oasis of Hope Why clear information matters when patients are overwhelmed The role of hope, mindset, faith, and joy during a cancer journey Stay Connected & Explore Learn More About Dr. Francisco Contreras and Oasis of Hope: Oasis of Hope: https://www.oasisofhope.com/ Dr. Francisco Contreras: https://www.oasisofhope.com/doctor/dr-francisco-contreras/ Request a Free Consultation: https://www.oasisofhope.com/contact-us/ Download Dr. Contreras' Free Cancer E-Book, The Art & Science of Undermining Cancer: https://www.oasisofhope.com/ Episode Sponsor: Learn more about Lemongrove Oil: https://www.lemongroveoil.com/ Connect with Conversations with a Chiropractor: Follow Us on YouTube: http://www.youtube.com/@ConversationswithaChiro Follow Dr. Stephanie on Facebook: https://www.facebook.com/wautierwellness Email for show-related inquiries and sponsorships: drstephaniewautier@yahoo.com Want to be a guest on Conversations with a Chiropractor? Send Stephanie Wautier a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/drstephanie Credits Podcast production by Brand|Sound. Start your podcast journey by emailing brandsoundpodcasts@gmail.com. Chapters 00:00 Introduction to Conversations with a Chiropractor 04:03 Meet Dr. Francisco Contreras 04:21 The Story Behind Oasis of Hope 08:08 Cancer Care Statistics and a Different Approach 08:46 Integrative Oncology and Treatment Options 10:47 Natural Therapies, Research, and FDA Approval 11:38 Immunotherapy and the Immune System 12:45 Science, Natural Therapies, and Patient Care 15:20 Rising Cancer Rates in Younger People 17:56 COVID Vaccination Questions and Cancer Concerns 21:20 Early Warning Signs and Cancer Prevention 22:23 Fruits, Vegetables, Exercise, and Risk Reduction 24:27 Stress, Immunity, and Spiritual Strength 26:05 Keeping Wellness Simple and Sustainable 29:36 Breast Cancer Screening, Mammograms, and Thermography 33:07 Biopsy Concerns, Risk, and Diagnostic Benefit 36:19 When to Contact Oasis of Hope 38:47 Referrals, Free Consultations, and Becoming a Patient 39:32 Dr. Contreras' Books and Free Cancer E-Book 42:10 Cancer Is Not Necessarily a Death Sentence 43:37 Hope, Mindset, and the Power of Joy 45:22 Final Thoughts and Closing
Most people assume that if a drug sits on the shelf at Costco or Walgreens, it must be pretty safe. But what if some of the most common over-the-counter (OTC) medications are among the riskiest drugs in America? On this vintage episode of Vitality Radio, Jared exposes the hidden dangers behind everyday pain relievers, sleep aids, and heartburn drugs—medicines that cause thousands of deaths every year when misused or taken long-term. You'll learn how a drug becomes “OTC,” what happens when pharmaceutical companies push for that switch, and why the FDA's approval process might not tell the whole story. Jared dives into the startling realities of PPIs like Prilosec, NSAIDs like ibuprofen, and acetaminophen (Tylenol)—uncovering their risks to the liver, kidneys, bones, and brain. He also discusses how marketing convinces consumers these drugs are harmless. Finally, Jared offers a resource for safe, natural alternatives for reflux, pain, inflammation, sleep, and immune support—options that nourish the body instead of depleting it. This episode will change the way you look at “harmless” OTC drugs and help you take real control of your health.Additional Information:#341: Your Digestive Health Supplement User's Guide. From IBS to Acid Reflux - Learn How to Balance Your Gut Health With Natural Products. #522: Q&A Show #5 - Jared Answers Your Questions About Energy and Sleep!#471: Boosting Your Immune System Ahead of Winter #553: Boswellia & Curcumin: Nature's Dream Team for Pain & Inflammation with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
Kevin Sabet debates Matt Johnson on the Illusion of Consensus podcast with host Rav Arora, covering Trump's psychedelic executive order, ibogaine, FDA approval, Right to Try, drug scheduling, and the future of psychedelic research. Sabet, a former White House drug policy advisor across the Clinton, Bush, and Obama administrations, argues for caution around psychedelics, marijuana policy, commercial incentives, and overstated medical claims. Johnson, a leading Johns Hopkins psychedelic researcher, responds on psilocybin studies, addiction treatment, depression, safety protocols, REMS, and why accelerated research may still follow the evidence. The discussion also covers Joe Rogan, RFK Jr., Marty Makary, Jay Bhattacharya, ketamine clinics, MDMA, MAPS, cannabis rescheduling, veteran suicide, and the risks of turning experimental drugs into public policy too quickly. Subscribe to Rav's Substack to get episodes straight to your inbox: https://www.illusionconsensus.com Chapters: 0:00 - Intro 2:05 - Sabet's Objection to Psychedelics 10:00 - Matt's Disagreement with Sabet 13:15 - Psychedelic Research Quality 21:10 - Kevin's Rebuttal 24:00 - Was Joe Rogan Wrong On Ibogaine's Efficacy 32:50 - Ibogaine Safety Concerns 40:50 - Could The Executive Order Go Too Far 46:10 - Rescheduling and FDA Approval
© 2020-2026 Ivy Podcast Discovery LLC
